Floatz logo

Eribulin

Chemotherapy-induced Alopecia

Dana-Farber Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Chemotherapy-induced Alopecia cohort.

Asset / SponsorPhaseRating
Minoxidil
Ohio State University Comprehensive Cancer Center
Phase 2CCC
Trastuzumab Deruxtecan
Dana-Farber Cancer Institute
Phase 2CCC

Same molecule, other indications

Eribulin is also rated in:

Locally Recurrent Breast CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →